Market news

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.

By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH NOTE Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated, measuring tablets and capsules as well as DehydraTECH

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City.

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebateKELOWNA, BC / ACCESS Newswire / September 1, 2026 / (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio ...

KELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective ...

By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH REPORT We update our report on Lexaria Bioscience Corporation (NASDAQ: LEXX) on the occasion of its third quarter fiscal 2026 Form 10-Q filing. Beyond the financial update, management elaborated on its business development activities, especially in the context of its participation at the 2026 BIO International Convention.